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Clinical Trials That Use Composite
End Points as Their Primary Outcome
It has become increasingly common for clinical trials in cardiovas-
cular medicine to use composite primary end points that often have
varying clinical importance. Time-to-event analyses, in which
mortality is but one of several outcomes, are particularly problem-
atic as the impact of death is clearly not equivalent to other
nonfatal outcomes such as rehospitalization (1). Another concern
is that indiscriminately combining mortality with other outcomes
in survival analyses may lead to biases related to “competing
risk” (2). Specifically, patients dying early in a clinical trial are
unable to experience future nonfatal outcomes.
To overcome these concerns, Cleland et al. (3) have used a novel
approach that relies on a composite outcome, namely “days lost due
to death or hospitalization,” over their eight-month follow-up
period. (They also separately reported one-year all-cause mortal-
ity.) By developing this composite outcome, the investigators have
avoided directly equating rehospitalization with death as in a
traditional event-free survival analysis, while at the same time
allowing for patients to have repeated rehospitalizations. This
approach allows clinicians to better appreciate the effect of home
telemonitoring on their composite end point and its overall clinical
and economic consequences.
Because of recent advances in cardiovascular medicine and lower
short-term mortality rates, it has become necessary for many
clinical trials to incorporate composite end points into their
protocols as a primary outcome in order to demonstrate biological
efficacy and statistical significance (1,2). We applaud Cleland
et al. (3) for using an innovative and rational composite end point
to evaluate a clinically relevant outcome in high-risk patients with
heart failure. Their meticulous reporting of each component of their
composite end point is also important and should be commended.
Of course, we wonder whether additional methodologies such
as “weighting” individual components of a composite end point—
days dead are counted more heavily than days hospitalized, for
example—may further improve these approaches. Such a strategy
of weighting outcomes was used effectively in the recent A-HeFT
(African-American Heart Failure Trial) study (4). Perhaps at a
minimum, separate reporting of individual components of a
composite primary end point should become routine and even
integrated into the CONSORT (Consolidated Standards of Re-
porting Trials) guidelines (1).
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Cleland et al. (1) for the first time demonstrated that telemedical
support in the follow-up of ambulatory patients with chronic heart
failure (CHF) compared to usual care is associated with survival
benefits as well as reduced length of hospitalization. The greatest
financial burden of CHF for society is associated with its high
hospitalization rates. Cleland et al. showed that hospitalization
rates were reduced in the group of patients receiving telemedical
care, but not in patients receiving nurse-led care. Their study sets
a new standard in telemedical research. The introduction of future
technology will not be possible without investigating the effects on
morbidity and mortality.
During the last five years, three generations of telemedical
systems have been introduced. The first-generation system was
based on sensors typically employing conventional telephone
systems to transfer data into central databases, which was then—
without analysis—transferred to physicians. The second-
generation system involved the use of additional sensors, but the
main difference was in the additional processing of the incoming
data. The system employed in the study by Cleland et al. (1)
represents this approach. The main structural problems of these
systems are the divided responsibility in all decision-making
processes and that direct patient contact is not utilized. Hence,
their medical impact is indirect and delayed.
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